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The speciation of several insulin-mimetic/enhancing VO(IV) and Zn(II) complexes in human blood serum
was studied and a comparison was made concerning the ability of the serum components to interact with
the original metal complexes and the distribution of the metal ions between the low and the high molec-
ular fractions of the serum. It was found that the low molecular mass components may play a larger role
in transporting Zn(II) than in the case with VO(IV). Among the high molecular mass serum proteins,
transferrin is the primary binder of VO(IV), and albumin is that of Zn(II). The results revealed that pro-
tein–ligand interactions may inﬂuence the metal ion distribution in the serum.
 2008 Elsevier Inc. All rights reserved.1. Introduction
Diabetes mellitus is currently one of the most widespread dis-
eases. The number of patients with diabetes is increasing year by
year, and in 2006 it reached approximately 250 million worldwide.
Over the last 25 years ions of metals such as Cr, Mn, Mo, W, V and
Zn have been reported to exhibit insulin-like effects. Among these
elements, V has proved to be one of the most efﬁcient in this re-
spect. Even simple inorganic V salts in oxidation state of +4 or +5
(e.g. vanadyl sulfate or sodium vanadate) have been shown to mi-
mic most of the physiological effects of insulin, such as the stimu-
lation of glucose uptake and metabolism in fat cells, the
enhancement of glycogenesis in the muscles and liver, the inhibi-
tion of gluconeogenesis from lipids or proteins, the stimulation of
fatty acid formation in the adipocytes [1]. The main advantage of
these V compounds over insulin is that they may be administered
orally. Accordingly, one aim of the research in this ﬁeld is to pre-
pare V compounds which can reach the target cells with high efﬁ-
cacy. Large numbers of VO(IV) and V(V) complexes have been
prepared and tested; one of them [VO(maltol)2] has passed clinical
phase 1 [2,3] and 2 [4] tests in Canada.ll rights reserved.
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), enyedy@chem.u-szeged.huThe experimental conditions of preparation of metal complexes
with potential biological activity usually differ considerably from
the milieu in living systems where they exert their biological ef-
fects. The solvent and the pH of the biological ﬂuids, cells and tis-
sues can differ signiﬁcantly. Metal complexes with well-deﬁned
stoichiometry and structure in the solid state will decompose or
dissociate after dissolution in biological ﬂuids and tissues and
sooner or later will attain the thermodynamic equilibrium state
determined by the stability constants of the metal complex exist-
ing at physiological pH. This thermodynamic equilibrium may re-
quire merely seconds in the case of labile metal complexes (e.g.
of Mn(II), V(IV) and Zn(II)), but it can take days or even weeks, as
in the case of Cr(III) or the isopolyacids or heteropolyacids of
W(VI)). Accordingly, complexes of the former metal ions will be
present in thermodynamic equilibrium shortly after their adminis-
tration; whereas the latter complexes may not change during the
time they spend in the body and will leave it without undergoing
any signiﬁcant change. These equilibrium speciations can be repre-
sented by the concentration distribution curves of the complexes
formed in the metal–ligand systems and calculated by the stability
constants determined in the usual solution speciation studies for
the given experimental conditions (e.g. a metal ion to ligand ratio
of 1:2 when the solid complex is a bis complex, and pH around
neutral for physiological conditions). The same solution composi-
tion can be achieved simply by making a sample containing the
metal ion and the ligand in the given composition and adjusting
the pH to the desired value. As an illustration, the decomposi-
tion/dissociation processes of the VO(IV)–maltolate system [5–7]
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Fig. 1. Concentration distribution curves for complexes formed in the VO(IV)–mal
(a) and Zn(II)–6-Me-pic (b) systems at a metal ion to ligand ratio of 1:2,
cmetal ion = 2 mM (based on data reported in [5–8].
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to ligand ratio of 1:2, due to the parallel proton competition reac-
tions, are displayed in Fig. 1 as a function of pH. It is seen in Fig. 1
that these neutral bis complexes will certainly decompose in the
acidic pH range, e.g. at the pH  2 of the gastric juice, and charged
species, the free metal ion and the mono complexes will predomi-
nate. Similarly, even at the pH of the blood serum, they do not keep
their integrity but partly hydrolyze, or, to a lesser extent, the Zn(II)
complex disproportionates tomono and tris complexes. One advan-
tage of the a priori preparation of such complexes is that in this
way they can be obtained in pure form without counter ions or
any impurities of the ligand, and the metal ion to ligand ratio
can be adjusted more accurately to the desired value.
Various endogenous or exogenous molecules with high afﬁnity
for the metal ion may also be present in biological systems, and
may partly or fully displace the original metal–binding ligand(s).
Thus the originally administered complex may undergo transfor-
mations during: (i) the absorption processes in the gastrointestinal
tract in the case of complexes administered orally, (ii) their trans-
port processes in the blood stream with the serum/plasma compo-
nents, and (iii) in the cell with its endogenous binding molecules.
The original carrier ligand(s) may be fully lost in the course of these
processes and the real biological/physiological activity is exerted
by a different chemical entity containing the metal.
2. Experimental
2.1. Chemicals
All ligands and proteins, such as human serum albumin (HSA)
and human serum apo-transferrin (apoTf), were commerciallyavailable products of puriss quality (Aldrich, Sigma and Fluka).
The concentrations of protein solutions were estimated from their
UV absorption (e280(apoTf) = 92.300 M1 cm1 and e280(HSA) =
36.850 M1 cm1 taken from Refs. [9] and [10], respectively. The
purity of the non-protein ligands was checked and the exact con-
centrations of the stock solutions prepared were determined by
the Gran method [11]. A ZnCl2 stock solution was made by
dissolution of anhydrous ZnCl2 in a known amount of HCl, and
its concentration was determined by complexometry via ethylene-
diaminetetraacetate complexes, and gravimetrically via the
oxinate.
2.2. pH-potentiometric studies
The pH-metric measurements for determining the stability con-
stants of the proton and Zn(II) complexes of the ligands were car-
ried out at an ionic strength of 0.2 M KCl and at 25.0 ± 0.1 C. The
titrations were performed with a carbonate-free KOH solution of
known concentration (ca 0.2 M). An Orion 710A pH-meter
equipped with a Metrohm combined electrode (type 6.0234.100)
and a Metrohm 665 Dosimat burette were used for the pH-metric
measurements. The electrode system was calibrated according to
Irving et al. [12] and the pH-meter readings could therefore be con-
verted to hydrogen ion concentrations. The water ionization con-
stant, pKw, was 13.76 ± 0.01 under the conditions employed. The
pH-metric titrations were performed in the pH range 2.0–11.0, or
until precipitation occurred in the samples. The initial volume of
the samples was 10.00 mL. The ligand concentrations varied in
the range 2–4 mM. In the binary systems, the metal ion to ligand
ratios were 1:1, 1:2 or 1:4 and in the ternary systems the metal:li-
gand A:ligand B ratios were 1:1:1, 1:2:1, 1:1:2 or 1:2:2. Calcula-
tions were always performed on the experimental titration data
determined before precipitation, with the computer program PSE-
QUAD [13]. The accepted ﬁtting of the titration curves was always
less than 0.01 mL; the uncertainties in the stability constants (as
±3SD values, i.e. three times the standard deviation) are given in
parentheses in the Tables. The samples were in all cases com-
pletely deoxygenated by bubbling puriﬁed argon through them
for ca 15 min before the measurements, and argon was also passed
above the solutions during the titrations. Duplicate titrations were
carried out and the reproducibility of titration points included in
the evaluation was within 0.005 pH unit throughout the pH range.
pH-potentiometric results were utilized to establish the stoichio-
metry of species and to calculate the stability constants (logb).
2.3. UV spectrophotometric measurements
UV spectrophotometric measurements on systems containing
HSA at 8–16 lM, and 4-(2-hydroxyethyl)piperazine-1-ethanesul-
fonic acid (HEPES) at 0.025 M were performed by titration with
2 mM ligand solutions. The HSA to ligand ratios were varied from
1:0.25 to 1:22. The samples were in all cases completely deoxygen-
ated by bubbling puriﬁed argon though them during the measure-
ments and thermostated at 25.0 ± 0.1 C. Control titration
measurements were carried out under the same conditions with
samples containing only HEPES buffer without HSA. A Unicam
Helios Alpha spectrophotometer was used to record the spectra
in the interval 220–350 nm. The path length was 1 cm.
2.4. Membrane ultraﬁltration and UV spectrophotometric
measurements
Samples were separated by ultraﬁltration through 10 kDa
membrane ﬁlters (Microcon YM-10 centrifugal ﬁlter unit, Amicon,
Millipore) according to a standard procedure [14]. In the protein–
ligand interaction studies, all 0.50 mL samples contained 200 lM
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Scheme 1. Formulae of the ligands studied in their fully protonated forms.
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7.4. For apoTf-containing samples, NaHCO3 was also used at
0.025 M. The ligand concentrations were varied from 50 lM to
1 mM. After the separation, the low molecular mass (LMM) frac-
tions were obtained. The ﬁltrates were diluted to 5.00 mL and
the concentrations of the non-bound ligand were determined by
UV spectrophotometry. Control samples containing the carrier
ligand and HEPES at the same concentrations but without the
protein were used to determine the accurate analytical concentra-
tion of the ligand. The binding constants were then calculated with
the computer program PSEQUAD [13] from the total and free con-
centration data pairs obtained at different protein–ligand ratios;
uncertainties in the stability constants (as ±3SD values) are given
in parentheses.
For Zn(II)-containing samples (i) 200 lM HSA (ii) 200 lM apoTf
or (iii) 630 lM HSA and 37 lM apoTf with the complex [Zn(II)A2]
at 200 lM in 0.1 M HEPES buffer at pH 7.4 and 0.025 M NaHCO3;
99 lM citric acid (cit), 77 lM histidine (His) and 33 lM cysteine
(Cys) were used. These concentrations (in case (iii)) are the rele-
vant total serum concentrations for both the LMM and the high
molecular mass (HMM) components [15]. Two parallel measure-
ments were made in all cases. After separation, LMM and HMM
fractions were obtained. The ﬁltrate contained the LMM species.
The Zn(II) content of the samples was determined by ICP-AES. Prior
to the analysis, the samples were digested in an acid mixture
containing 0.5 mL of conc. HNO3 and 0.5 mL of 30% H2O2 (Supra-
pur, Merck). The resulting solutions were transferred into
5.00 mL volumetric ﬂasks and made up to the mark with Millipore
MilliQ quality deionized water. The analysis was performed at the
Zn I 213.86 nm emission wavelength using a Jobin-Yvon 240 all-
argon spectrometer equipped with a Teﬂon V-groove nebulizer
and a Gilson Minipuls III peristaltic pump. Two determinations
on each solution were carried out with 2-point background correc-
tion, 4-point direct calibration and Gaussian spectral drift-com-
pensation. Standard solutions for calibration were prepared from
a 1 g L1 commercial Zn(II) stock solution (Merck) through dilution
with Millipore MilliQ quality deionized water.0.0
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Fig. 2. Calculated VO(IV) speciation in the blood serum as a function of the total
complex concentration; concentrations of serum components relate to the total
serum [15]: [VO(IV)(maltol)2] (a) and [VO(IV)(dhp)2] (b) (pH 7.4,
cðHCO3 Þ = 0.025 M, at 25 C) (based on data reported in [5–7,18].3. Results and discussion
3.1. Biospeciation of antidiabetic VO(IV) complexes
In the past few years we have studied potential transformations
of several antidiabetic VO(IV) and Zn(II) complexes in biological
systems [5–8,16]. The structures of the ligands are shown in
Scheme 1. Here, only their reactions that occur with serum compo-
nents as active VO(IV) binders during their transport in the blood-
stream are considered. The interactions of several potential
antidiabetic compounds with HMM protein constituents, e.g. HSA
and apoTf, and LMM constituents (the most potent, negatively
charged O-donor binders), e.g. lactate, phosphate, oxalate and cit-
rate, are discussed brieﬂy.
Their possible transformations were followed by pH-potenti-
ometry in order to describe the reactions with the LMM compo-
nents quantitatively, while spectroscopic methods were applied
to characterize the interactions with the HMM protein compo-
nents. Ultraﬁltration served to separate metal ion contents bound
by the HMM and LMM fractions.
Then, in the knowledge of the speciation description of these
antidiabetic complexes with the constituents of the various biolog-
ical ﬂuids, modeling calculations were carried out to identify the
actual chemical forms existing under the serum conditions. The re-
sults were discussed in detail previously [5,6]. The results are now
represented in a new form in Fig. 2 showing that the roles of the
different serum components in the transport of the metal (com-plex) with biological activity are strongly concentration-
dependent.
It was reported earlier [5] that at c([VO(L2)] 6 50 lM) (i) most of
the carrier ligands are displaced by serum components; only the
pyridinone derivative dhp is a strong enough carrier to preserve
a signiﬁcant proportion of the VO(IV) in the original complex; (ii)
of the two important HMM binders, transferrin (Tf) is much more
530 T. Kiss et al. / Journal of Inorganic Biochemistry 103 (2009) 527–535efﬁcient than albumin and displaces a signiﬁcant portion of the ori-
ginal carrier from the complex; (iii) among the LMM binders, cit-
rate is the only ‘‘active” component, able to inﬂuence the
solution state of these antidiabetics. However, at higher complex
concentrations, when Tf is fully saturated with VO(IV), the excess
of the complex will interact with other serum components too,
and the role of the original complex and the ternary complexes
with LMM serum constituents in metal ion transport increases,
as shown in Fig. 2. Interestingly, the other serum protein albumin
does not have signiﬁcant role in the transport, even in the mM con-
centration range. It must be mentioned, that in contrast with our
results, via in vivo blood circulation monitoring-EPR measurements
in rats, and analysis of the EPR spectra Yasui et al. [17], concluded
that [VO(IV)(6-Me-pic)2] reacts with albumin, and that VO(IV) is
bound to albumin under serum conditions. It should be empha-
sized, however, that they used a rather high VO(IV) concentration
(400 lM), which means that after saturation serum Tf, a large
amount of VO(IV) remained in excess available to react with albu-0.0
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Fig. 3. Summed concentration distribution curves for complexes formed in the Zn(II)–6-M
Zn(II)–dipic–His (e) and Zn(II)–dipic–Cys (f) systems at a ratio of 1:2:2, cZn(II) = 2 mM.min. Moreover, a careful analysis of Figs. 3 and 4 in Ref. [17] does
not unambiguously support the interaction of VO(IV) with albu-
min; it may be recalled that the differences in the EPR parameters
of the VO(IV) complexes of Tf and HSA are not so large [9,19] to be
suitable for a clear distinction of the various protein-bound compo-
nents by a simple comparison of the spectral parameters. We con-
sider that the ultraﬁltration measurements and anion-exchange
chromatographic separations carried out with human blood sam-
ples [5,6,18], clearly demonstrated the exclusive binding of VO(IV)
to Tf in the blood serum.
A qualitative conﬁrmation of the result was achieved by mem-
brane separation of the LMM and the HMM-bound VO(IV) using a
10 kDa membrane in the [VO(mal)2]–protein and [VO(pic)2]–pro-
tein samples. The results showed that apoTf can completely dis-
place the carrier ligand from the complex [VO(pic)2], while HSA
can hardly to do the same [18]. This is reﬂected in the conditional
stability constants of the complexes formed between VO(IV) and
apoTf and between VO(IV) and HSA, which are 14.3(6) and 10(1),0.0
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e-pic–cit (a), Zn(II)–6-Me-pic–His (b), Zn(II)–6-Me-pic–Cys (c), Zn(II)–dipic–cit (d),
Σ[Zn(II)]
Σ[Zn(A)]
Σ[Zn(cit)]
Σ[Zn(His)]
Σ[Zn(Cys)]
Σ[Zn(A)(cit)]
Σ[Zn(A)(His)]
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Fig. 4. Summedmolar fraction of Zn(II) (the sum of the Zn(II) fractions bound in the binary complexes with ligand A or B and those bound in the ternary complexes of ligand A
and B) in hypothetical systems containing Zn(II) (100 lM); dipic (a); or 6-Me-pic (b); or mal (c) (200 lM); cit (99 lM); His (77 lM) and Cys (33 lM) at pH 7.4.
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very different from those reported by Chasten et al., who found
K(VO–Tf)/K(VO–HSA)  6 [20].
The speciation results obtained from modeling calculations
were fully conﬁrmed by in vitro studies with human serum sam-
ples. After incubation with human serum the different antidiabetic
complexes were separated on anion-exchange column and the
VO(IV) contents of the separated fractions were measured by
ICP-MS. It emerged that all the VO(IV) complexes and also VOSO4
were bound only in the Tf fraction, and HSA did not bind a measur-
able amount of the metal ion. This is complete conﬁrmation of our
modeling measurements and calculations. Interestingly, Tf was
able to bind VO(IV) in different isoforms, as identiﬁed by MALDI–
TOF measurements [5,18]. It is noteworthy that similar isoforms
were detected by Chasteen et al. [20] by EPR.
Even though 100 V(IV,V) compounds have been prepared and
found to be active in insulin-mimetic/enhancing behavior only a
single compound has entered clinical studies [2–4].
Why do pharmaceutical companies show little interest in V-
containing insulin like compounds? One reason is the potential
nonspeciﬁc phosphate-inhibitory action of V(V, IV), inﬂuencing a
cascade of phosphorylation/dephosporylation steps involved in
glucose transport into the cell and its metabolism in the cell. Non-
speciﬁc actions are always problems in medication, as they mean
side-effects which have to be cured. However, this is not a major
objection as there are many drugs with nonspeciﬁc action in every-
day use, such as the anticancer cytotoxic drugs, including the plat-
inum compounds, or the gold compounds used in the treatment of
rheumatoid arthritis. Another reason (which may be more impor-
tant) is fact that the pharmacodynamics of these V compounds
have been not completely explored. It is not completely known
what happens to these inorganic salts when they enter the body,
when they are absorbed, when they enter the cell, where theyTable 1
Stability constants (logb) for the mixed-ligand complexes formed in the Zn(II)–ligand A–lig
and [ZnA] at 25 C; I = 0.20 M KCla.
[ZnABH] [ZnAB] [ZnABH1]
6-Me-pic
cit 12.57(18) 8.30(6) 0.7(2)
His 15.6(2) 10.06(6) 1.18(3)
Cys 19.01(8) 13.08(3) 4.17(3)
Dipic
cit – – 0.6(2)
His 18.31(15) 11.85(21) 1.77(6)
Cys 21.51(10) 14.60(24) 4.08(18)
a Uncertainties (3SD) are shown in parentheses for the complexes determined in th
calculations were taken from [8,16].
b Fitting parameter (mL).
c At pH 7.4; Zn(II):ligand A:ligand B ratio = 1:2:2, cZn(II) = 2.0 mM.may accumulate, how fast and in what form they are excreted,
etc. This necessitates progress from chemists, biochemists and
pharmacologists who are now working in this ﬁeld with increasing
activity.
3.2. Biospeciation of antidiabetic Zn(II) complexes
In parallel with these studies, there is increasing interest in
more ‘‘friendly” metal ions too, e.g. Zn(II). Zn(II) is an essential ele-
ment and, although it is not so efﬁcient in insulin-mimesis as
V(IV,V), it may be accepted more easily by members of the medical
profession. Sakurai et al. performed numerous studies on the anti-
diabetic activity of Zn(II) complexes both in vivo and in vitro
[21,22]. We carried out similar aqueous solution studies with Zn(II)
complexes corresponding to V complexes, which exhibit activity at
the 100 lM level [16,21,22]. The potential transformation pro-
cesses of the complexes in the serum were studied by pH-metry,
various spectroscopic techniques and Ultraﬁltration, by separating
the LMM and HMM-bound metal ion fractions [8,16].
3.2.1. Ternary complex formation processes in Zn(II) – carrier ligand –
LMM component systems
The formulae of the ligands studied are shown in Scheme 1. Bin-
ary complex formation of Zn(II) with carrier ligands, dipic and 6-
Me-pic or with LMM components of the serum, e.g. Cys, His and
cit were studied in our laboratory earlier [8,16]. Accordingly, the
stoichiometry and stability constants are presented in Table 1 only
for the ternary complexes formed between them, which were
determined in this study. As concerns the binary complexes, it is
noteworthy that, while 6-Me-pic coordinates to Zn(II) as a biden-
tate ligand via (O,N) donors to form mono, bis and tris complexes,
dipic furnishes mostly a high-stability bis complex in a tridentate
coordination mode through the pyridine-N and the neighbouringand B ternary systems and some molar fractions calculated for the complexes [ZnAB]
F. pb No. [ZnAB]%c
P
[ZnA]%c
4.17  103 452 58 24
3.88  103 529 28 24
3.38  103 610 20 5
2.89  103 430 0 98
3.43  103 475 4 92
4.25  103 417 6 80
e present work. See Section 2.2. Constants of the binary complexes used for the
532 T. Kiss et al. / Journal of Inorganic Biochemistry 103 (2009) 527–535carboxylic O donor atoms, this being the predominant species in
the interval pH 3–10 [16]. Cys, cit and His were chosen for this
study according to their Zn(II)-binding abilities at pH 7.40 and
their serum concentrations, since they are the most prominent
Zn binders among the blood LMM compounds [15,23]. Coordina-
tion modes in the binary complexes of Cys, His and cit with Zn(II)
were also discussed in a previous paper [16]. In the case of mal,
dhp and pic, all three serum components were found to be able
to compete for the binding sites of Zn(II) through partial or com-
plete displacement of the carrier ligand, and ternary complex for-
mation is important at the physiological pH.
Overall stability constants for the mixed-ligand complexes
formed in the systems of Zn(II)–dipic or Zn(II)–6-Mepic and the
LMM components are collected in Table 1. The experimental titra-
tion data revealed the formation of the species [ZnABH], [ZnAB]
and [ZnABH1]. As regards the proton dissociation constants of li-
gands A and B [16], the logKZnABHZnAB values and the fact that complete
deprotonation of the ligand is necessary for the coordination of 6-
Me-pic, it can be concluded that the proton in the complexes
[ZnABH] is most probably from ligand B. In the complexes [ZnAB],
6-Me-pic and dipic presumably coordinate via the usual (N,O) and
(O,N,O) modes, providing a possible tridentate binding of ligand B,
as Scheme 2 shows. Since there are no further dissociable protons
in the coordinated ligands in the complexes [ZnAB], [ZnABH1] is
formed by the deprotonation of a coordinating water molecule,
or by the coordination of a hydroxide by displacement of a donor
atom, and it can therefore be regarded as [ZnAB(OH)]. Further-
more, the lack of formation of species [ZnA2B] or [ZnAB2] was dem-
onstrated with 6-Me-pic and dipic, in contrast with mal, dhp or pic.
In the case of dipic the tridentate coordination of the ligand, and in
the case of 6-Me-pic the relatively bulky methyl group is responsi-
ble for the exclusive formation of the ternary complexes [ZnABHx].
The extent of mixed-ligand complex formation and the pH re-
gions in all ternary systems studied are compared by the use of
summed concentration distribution curves in Fig. 3.
Such curves show the pH dependence of the summed concen-
tration of the species formed with only ligand A or ligand B, or
bound in the mixed-ligand complexes. At ﬁrst glance, dipic
undoubtedly undergoes a lower extent of formation of ternary
complexes than does 6-Me-pic, due to the outstanding high stabil-
ity of the bis complex [Zn(dipic)2]2. Cys and His are able to substi-
tute one or two molecules of dipic only to a small extent above pH
7, while the formation of the complexes type [Zn(dipic)(cit)Hx] is
almost negligible. In contrast, in the case of 6-Me-pic, the forma-
tion of mixed-ligand complexes is quite considerable in a wide
pH range (pH 6–8), not only with Cys and His, but also with cit,
and thus the Zn(II) binding abilities of the serum components
and this carrier ligand are comparable in the slightly acidic pH
range. Similarly as in the systems Zn(II)-dipic-Cys or His, 6-Me-
pic is also displaced to a great extent by Cys or His above pH 7–8
owing to the relatively high stability of the parent bis complexes
of these LMM serum components. The data presented in Table 1
relating to the molar fractions of [ZnAB] and the parent complexes
of the carrier ligands at physiological pH show that Zn(II) is mostly
bound to dipic in all cases, while the extents of ternary complex
formation of 6-Me-pic with cit, His and Cys are comparable toZn
OH2
N
H2N
N
O
COO-
(Im)
Zn
O
N
H2N
COO-
(Im
[Zn(6-Me-pic)(His)] [Zn(dipic)
Scheme 2. Proposed binding modes of the mixed-ligand complexthose of mal, dhp and pic at equimolar concentrations of the li-
gands [8]. The ﬁnal results of our modeling calculations on the dis-
tribution of Zn(II) in a hypothetical system containing LMM
components in their serum concentrations at pH 7.4 are depicted
in Fig. 4. It is seen that in the case of 6-Me-pic and mal a signiﬁcant
amount of Zn(II) is bound in mixed-ligand complexes, mainly with
His and Cys, and relatively little Zn(II) is retained in the original
insulin-mimetic complex. On the other hand, as an excellent Zn(II)
binder, dipic has the ability to keep most of the metal ion in the
high stability parent bis complex.
3.2.2. Model calculations versus ultraﬁltration – ICP-AES studies on
artiﬁcial serum model
The role of serum proteins in the Zn(II) distribution is obviously
very important, besides that of the LMM components. Among the
serum proteins, HSA, Tf and a-macroglobulin have signiﬁcant
Zn(II)-binding abilities [24–26]. Since HSA is considered the pri-
mary Zn(II) binder in most papers, and the less important role of
Tf is still questioned [26,27], the effects of HSA and Tf on the Zn(II)
distribution of samples containing insulin-mimetic complexes
were studied. Zn(II)-binding ability of a-macroglobulin is also sig-
niﬁcant and should be considered further.
HSA is the most abundant protein in the blood (630 lM), and is
of great importance in the transport and storage of different kinds
of substances, such as fatty acids, vitamins, drugs and metal ions.
HSA has a conditional Zn(II) binding constant of logK0  7.1–7.9
at physiological pH [28,29], and Zn(II) is located between domains
I and II. Zn(II) exhibits irregular geometry at its binding site, which
involves two carboxylates, two His N donor atoms and a water
molecule. Tf is able to bind two Zn(II) ions at the Fe(III) binding
sites also with high afﬁnity (logK 01 ¼ 7:8;logK 02 ¼ 6:4, pH 7.40
[30]), but the presence of the synergistic HCO3 is crucial for the
binding. Although Tf is a less abundant protein in the serum
(37 lM), and around one-third of the metal-binding sites are occu-
pied by Fe(III), so the effect of this protein on the Zn(II) distribution
can not be disregarded.
In order to obtain information on the Zn(II) biodistribution in an
artiﬁcial serum containing an insulin-mimetic complex, modeling
calculations were performed as in our previous studies [8]. The cal-
culations involved the formation of the parent complexes of the
carrier ligands, the parent complexes of the LMM components,
their mixed-ligand species and Zn(II)–serum protein complexes
at physiological pH in the presence of NaHCO3 (0.025 M). The con-
centrations of the proteins and LMM components (His, Cys and cit)
were chosen according to the serum conditions. The effects of the
two serum proteins were also calculated in samples containing
only one of the serum proteins (Cases 1 and 2 in Table 2). The con-
centration of the insulin-mimetic Zn(II) complexes was 200 lM as
the complexes showed biological activity in in vitro measurements
at 200–300 lM [31]. The results of the computational modeling
calculations in the cases of 6-Me-pic and dipic are collected in Ta-
ble 2 in the column ‘‘Calc. I”.
These modeling calculations demonstrate that Zn(II) is mostly
bound to the LMM fraction of the serum in the case of dipic, and
to the HMM fraction in the case of 6-Me-pic at equimolar concen-
trations of the insulin-mimetics and the protein (Cases 1 and 2)N
O
)
Zn
O
S-
H2N
N
O
(COO-) H2O
(His)] [Zn(dipic)(Cys)] 
es [Zn(6-Me-pic)(His)], [Zn(dipic)(His)] and [Zn(dipic)(Cys)].
Table 2
Measured and calculated (I: without HSA–ligand; II: with HSA–ligand interactions) percentage of Zn(II) bound to different fractions of the ultraﬁltered samples containing Zn(II)
(0.20 mM)–dipic (or 6-Me-pic) (0.40 mM)–LMM components under serum conditions (cit: 99 lM; His: 77 lM; Cys: 33 lM)–HSA (0.20 mM or 0.63 mM) and/or apoTf (0.20 mM or
37 lM) at pH 7.40; t = 25 C (see text).
Dipic 6-Me-pic
Meas. Calc. I Calc. II Meas. Calc. I Calc. II
Case 1
0.20 mM HAS
LMM
P
47
P
85
P
51
P
4
P
12
P
7
P
[ZnA] 85 45
P
[ZnA(Cys)] 6 2
P
[Zn(Cys)] 6 6 5
HMM
P
53
P
15
P
49
P
96
P
88
P
93
bound to the proteins
P
[Zn–HSA] 15 88 4
P
[Zn–HSA-A] 49 89
Case 2
0.20 mM apoTf
LMM
P
74
P
82
P
6
P
3
P
[ZnA] 78
P
[Zn(Cys)] 4 3
HMM
P
26
P
18
P
94
P
97
bound to the proteins
P
[Zn–apoTf] 18 97
Case 3
0.63 mM HSA + 37 lM apoTf
LMM
P
3
P
78
P
2
P
7
P
2
P
2
P
[ZnA] 78
P
[Zn(Cys)] 2 2 2
HMM:
P
97
P
22
P
98
P
93
P
98
P
98
bound to the proteins
P
[Zn–HSA] 19 32 88 35
P
[Zn–apoTf] 3 10 10 10
P
[Zn–HSA-A] 56 53
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pared with that of 6-Me-pic. Under the serum conditions (Case 3
in Table 2), different distributions can be calculated with the two
carrier ligands, similarly as above. Among the LMM components,
the degree of complexation is considerable only with Cys. In order
to conﬁrm the results of the modeling calculations, ultraﬁltration–
ICP-AES measurements were performed on samples with the same
compositions. Following separation of the HMM and LMM frac-
tions by ultraﬁltration, the Zn(II) contents of these fractions were
determined by the ICP-AES method. The experimental results are
presented in Table 2. It can be concluded that the measured and
calculated percentage distributions of Zn(II) are in good agreement
in the case of apoTf (within experimental error), whereas the HSA-
containing samples display much more signiﬁcant deviations,
especially in the case of dipic. As an example, according to the cal-
culations, dipic should be able to retain Zn(II) in the LMM fraction
with higher efﬁcacy than obtained by measurement, which draws
attention to the incorrectness of the model used. It was therefore
assumed that interactions between the serum proteins and carrier
ligands can not be neglected and protein–ligand complexes should
also be included in the modeling, but no literature data are avail-
able on these interactions.
3.2.3. Protein–ligand interactions
First of all, apoTf–carrier ligand interactions were studied by
means of ultraﬁltration–UV spectrophotometric measurements;
no measurable binding of 6-Me-pic, mal, dhp or pic to this serum
protein was detected. Dipic participated in a relatively weak bind-
ing to apoTf (logK0 = 3.5(1) or Kd = 340 lM at pH 7.40, t = 25 C);
however, no appreciable interaction could be observed in the pres-
ence of 0.025 M NaHCO3. Ligand binding to apoTf can therefore beneglected and most probably has no effect on the biodistribution of
Zn(II) under serum conditions. This ﬁnding is supported by the
good ﬁt of the calculated and measured data in Table 2 in the case
of the apoTf-containing samples (Case 2).
As a well-known drug carrier, HSA is able to bind mainly nega-
tively charged, aromatic carboxylic acids or large heterocyclic com-
pounds and to transfer them to the target tissues. HSA can
solubilize poorly soluble drugs in the circulatory system via its li-
gand-binding ability and it can also delay the metabolic clearance
of therapeutic agents, thereby providing a longer lifetime [32]. HSA
binds fatty acids, which can modify the binding ability towards
drugs via conformational changes at the drug binding sites [33];
hence, non fatty acid-free HSA was applied for our studies.
Difference UV spectra were recorded for the ligands and HSA–
ligand-containing samples as depicted in Fig. 5 in the case of 6-
Me-pic at different ligand to protein ratios at physiological pH.
Measurable concentration-dependent absorbances were obtained
in the cases of 6-Me-pic and dipic, due to the changes in the elec-
tronic structure of the ligand or the protein or both, as a conse-
quence of the interactions between HSA and the carrier ligands.
When the spectra of the ligand and the protein are additive, the
absorbance recorded for the HSA–ligand sample minus the sum
of the spectra of HSA and the ligand alone would be zero.
To determine the maximum number of ligands binding to HSA
and the strength of the interaction, ultraﬁltration–UV spectropho-
tometric measurements were carried out. Mixtures of HSA and li-
gand at different ratios were used and the non-bound ligand
fraction was separated by ultraﬁltration from the HSA and HSA–li-
gand complexes in the HMM fraction. The UV spectra of the LMM
fractions were always compared with the reference spectra of the
samples containing the ligand without protein in an analytical
Table 3
Conditional overall and stepwise stability constants (logb0 , logK0) of HSA–ligand(A)
complexes calculated from ultraﬁltration–UV measurements, a together with those of
Zn(II)–HSA–ligand complexes calculated on the basis of statistical considerations (see
text)b at pH 7.40 (HEPES); t = 25 C.
Dipic 6-Me-pic Mal Pic
logb0 (HSA-A) 6.0(2) 5.16(3) 3.47(3) 4.33(3)
logb0 (HSA-(A)2) 8.9(2) 8.28(3) – –
logK0 (HSA-A) 6.0 5.16 3.47 4.33
logK0 (HSA-(A)2) 2.9 3.12 – –
logb0 (Zn–HSA-A) 13.3 12.46 10.77 11.63
logb0 (Zn–HSA-(A)2) 16.2 15.58 – –
a Uncertainties (3SD) are shown in parentheses for the complexes determined in
the present work. See Section 2.2. In the case of dipic, the stronger interaction with
HSA results in very low concentrations of the non-bound ligand at lower ligand to
protein ratios and therefore the uncertainties in the data were much higher as
compared with those for the other ligands.
b logb0(Zn–HSA-A) = logb0(HSA-A) + logb0(Zn(II)–HSA); logb0(Zn(II)–HSA) = 7.30
[28,29].
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Fig. 7. Equilibrium concentration of the bound ligand versus free ligand (calculated
from the UV spectra of ultraﬁltered HSA and 6-Me-pic-containing samples
compared to those of the reference samples at various HSA/6-Me-pic ratios at pH
7.4, HEPES (0.10 M)), with the values calculated on the basis of the determined
associative conditional binding constants (dashed line).
-0.06
-0.05
-0.04
-0.03
-0.02
-0.01
0
260 280 300 320 340
wavelength (nm)
D
iff
er
en
ce
 A
bs
or
ba
nc
e
1µM
4µM
6µM
8µM
24µM
40µM
48µM
-0.06
-0.04
-0.02
0
0 20 40 60
concentration of 6-Me-pic (µM)
D
iff
. A
bs
.
 
at
 
27
1 
nm
Fig. 5. Difference UV absorbance spectra recorded for the HSA–6-Me-pic system
compared to that of 6-Me-pic alone at different HSA to ligand ratios, pH 7.40 HEPES
(0.025 M); cHSA = 8 lM; c6-Me-pic = 1–48 lM. The inset shows the difference absor-
bance values at 271 nm.
534 T. Kiss et al. / Journal of Inorganic Biochemistry 103 (2009) 527–535concentration equal to that in the ultraﬁltered samples. Some rep-
resentative UV spectra for the HSA–dipic system are illustrated in
Fig. 6.
Ratio of the spectrum of the LMM fraction to that of the refer-
ence sample gives the ratio of the number of moles of non-bound
ligand to the total number of moles of the carrier ligand. From
these data, the stoichiometry and conditional stability constants
were calculated; and the results are listed in Table 3. It is notewor-
thy that formation of species with HSA:ligand composition of 1:2
besides 1:1 involved in the model signiﬁcantly increased the ﬁtting
between the experimental and calculated concentrations in the
case of dipic and 6-Me-pic.
The measured equilibrium concentrations of the free and bound
ligand together with the values calculated by using the determined
stability constants are presented in Fig. 7.
It can be concluded that dipic and 6-Me-pic are able to form
both 1:1 and 1:2 complexes with HSA, whereas only 1:1 complexes
were found in the cases of mal and pic [16]. Dhp does not exhibit a
measurable tendency to bind to HSA, and for this reason constants
for HSA–dhp species could not be determined. One possible expla-
nation of this is that dhp is neutral (HAo) at physiological pH, while
dipic, 6-Me-pic and pic are completely deprotonated (A2; A and
A, respectively) and HSA tends to bind negatively charged com-
pounds [31,32]. In the case of mal, 10% of the ligand is deproto-
nated at the pH studied, displays only a moderate binding ability
towards HSA. However, besides the actual charge of the ligands,0.00
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Fig. 6. Representative UV spectra recorded for the LMM fractions of the ultraﬁl-
tered samples of HSA–dipic (solid black line), with the corresponding reference
spectra of dipic samples (dashed line). Original sample composition: HSA (200 lM
or 0 lM for the references); dipic (1000 (a); 500 (b); 250 (c) and 190 lM (d)) at pH
7.4 (HEPES (0.10 M)).other factors, such as the size and the lipophilic character, are also
important factors in binding [32,33].
Our preliminary results obtained with the use of site marker
compounds such as warfarin and dansylglycine show that the
interaction of these carrier ligands with HSA most probably takes
place at the typical drug-binding sites of the protein, i.e. Sudlow
sites I and II, which are located quite distant from the Zn(II)-bind-
ing site. This is the reason why the binding of the metal ion and the
ligands may be regarded as independent interactions. Hence the
binding constants for the HSA–ligand–Zn complexes can be calcu-
lated from statistical considerations [34]; these are included in
Table 3. However, the formation of ternary complexes via the Zn(II)
centre (e.g. the HSA–Zn–ligand complex) is neglected in this mod-
el; studies related to this assumption are currently in progress in
our laboratory.
With the use of all the binding constants featuring in Table 3,
the Zn(II) distributions between the HMM and LMM fractions were
recalculated and are shown in Table 2 as ‘‘Calc. II” values. When the
HSA–ligand interactions were taken into account a better ﬁt with
the experimental data was obtained. Fig. 8 presents the percentage
distribution of Zn(II) bound to the HMM fractions with all the
carrier ligands studied, when the HSA–ligand interaction is ne-
glected or considered. It can be concluded that the HSA–carrier
ligand interactions do not have a signiﬁcant effect on the Zn(II)
020
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Fig. 8. Measured and predicted percentage distributions of Zn(II) bound to the high
molecular mass fractions in the dipic, Me-pic, mal, dhp and pic-containing systems
at pH 7.40 cZn(II) = 200 lM, cligandA = 400 lM, ccit = 99 lM, cHis = 77 lM, cCys = 33 lM,
cNaHCO3 ¼ 0:025 M, cHEPES = 0.10 M, cHSA = 630 lM, cTf = 37 lM. White bar: measured
values; grey bar: calculated without HSA–ligand interactions; black bar: calculated
with HSA–ligand interactions. Experimental data for mal, dhp and pic are taken
from [8].
T. Kiss et al. / Journal of Inorganic Biochemistry 103 (2009) 527–535 535distribution, except for dipic. As dipic forms a very high stability bis
complex with Zn(II), a much lower percentage of the HMM fraction
would be expected without the protein–ligand interaction (grey
bar), but this ligand binds to HSA most strongly among these li-
gands and HSA can be considered a competitor with Zn(II) for
the dipic ligand which results in less dipic available for Zn(II)
remaining in the LMM fraction; thus a higher Zn(II) content of
the HMM fraction (black bar) is measured.
4. Conclusions
Vanadium and zinc, either as inorganic salts or even in the form
of organic complexes are both active as insulin-enhancing agents,
although the former seems to be more efﬁcacious biologically
[35]. This may suggest somewhat different modes of action. Prob-
ably, both act as phosphatase inhibitors [21], but they interfere at
different points of the rather complex glucose metabolism, which
involves numerous phosphorylation/dephosphorylation reactions.
During chronic treatment with the corresponding complex in
the appropriate dose for several weeks the usual plasma vanadium
concentration of rats increases to a maximum level of 10 lM
VO(IV) [21,22], while the corresponding maximum for Zn(II) is
around 100–200 lM [22]. At such metal concentrations practically
no VO(IV) is bound to the LMM components of serum [5,6], while
Cys and His can bind even 40% of the total Zn(II) under serum con-
ditions [8]. Furthermore, VO(IV) binds mostly to Tf, and Zn(II)
mostly to HSA. Accordingly, different transport mechanisms can
be assumed for the two metal ions to reach the target cells.
5. Abbreviations
6-Me-pic 6-methylpicolinic acid
apoTf apo-transferrin
cit citric acid
Cys cysteine
dhp (3-hydroxy-1,2-dimethyl-pyridinone)
dipic 2,6-pyridine dicarbocylic acid
HEPES 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid
His histidine
HMM high molecular mass
HSA human serum albuminICP-AES inductively coupled plasma atomic emission spectroscopy
ICP-MS inductively coupled plasma mass spectrometry
LMM low molecular mass
mal maltol
pic picolinic acid
Tf transferrin
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